Skip to main content
. Author manuscript; available in PMC: 2019 Oct 15.
Published in final edited form as: Mol Cell Endocrinol. 2018 Feb 8;474:35–47. doi: 10.1016/j.mce.2018.02.005

Figure 4. The effect of raloxifene on ALP activity and mineralization in WT and Pyk2-KO OBs.

Figure 4

WT and Pyk2-KO OBs were cultured under osteogenic conditions with or without 0.1, 1.0 and 10 nM raloxifene for 28 days. The treatment duration was based on the most robust E2 effects, while the raloxifene concentrations were determined based on pilot studies and published literature (Lin et al., 2004,Matsumori et al., 2009). Assays were performed in triplicate and repeated 3 or more times. The error bars are mean ± SEM. A) ALP activity and B) Calcium deposition. Statistical significance of p<0.05 is indicated (*) for treatments within a genotype and (#) indicates significance between genotypes for the same raloxifene concentration.